Nothing said here yet.
to join the conversation.
Activists recently filed disclosures with the SEC that included Privia Health Group (PRVA), putting fresh attention on the physician-enablement specialist and how its shares trade around the latest ownership updates.
Privia Health Group shares most recently closed at US$19.85, and the weaker run in the stock raises a straightforward question for investors who care about valuation.
Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Privia Health (NASDAQ:PRVA) and its peers.
Privia Health has been treading water for the past six months, recording a small loss of 1.7% while holding steady at $21.63. The stock also fell short of the S&P 500’s 11.3% gain during that period.
Dr. Ernest Brings Significant Value-based Care and Clinical ExpertiseARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D.
Privia Health’s second quarter results were met with a negative market reaction as investors digested the company’s strong revenue growth alongside a material shortfall in non-GAAP profit relative to Wall Street expectations.
Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year.
Net income surged 237% while attributed lives grew 19%, signaling strong operational momentum.
Healthcare tech company Privia Health Group (NASDAQ:PRVA) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 21.4% year on year to $632.6 million. Its non-GAAP profit of $0.19 per share was 22.2% below analysts’ consensus estimates.
In the past week, Privia Health Group, Inc. reported second-quarter 2026 results showing sales of US$632.63 million and net income of US$9.05 million, both higher than a year earlier, and modestly higher earnings per share from continuing operations.
Privia Health Group (NASDAQ:PRVA) reported second-quarter results marked by double-digit growth in implemented providers, attributed lives and practice collections, while adjusted EBITDA rose 29% from a year earlier.